MRT-8102
IL-1β/NLRP3 driven Inflammatory Diseases
Key Facts
Indication
IL-1β/NLRP3 driven Inflammatory Diseases
Phase
Phase 1
Status
Active
Company
About Monte Rosa Therapeutics
Monte Rosa Therapeutics is on a mission to redefine the druggable genome by developing precision molecular glue degraders (MGDs) that eliminate, rather than inhibit, pathogenic proteins. The company has rapidly advanced from its 2018 founding to a public entity with multiple clinical-stage assets, underscored by a landmark $2.1B+ partnership with Novartis for its lead immunology candidate, MRT-6160. Its strategy centers on leveraging the proprietary QuEEN™ discovery engine—integrating AI, structural biology, and proteomics—to systematically target novel protein surfaces and build a broad pipeline across high-value therapeutic areas.
View full company profileTherapeutic Areas
Other IL-1β/NLRP3 driven Inflammatory Diseases Drugs
| Drug | Company | Phase |
|---|---|---|
| Next Generation (NEK7) | Monte Rosa Therapeutics | Preclinical |